There are 2934 resources available
2937 - Phase 1 Study of AMG 510, a Novel Molecule Targeting KRAS G12C Mutant Solid Tumors
Presenter: Ramaswamy Govindan
Session: Poster Discussion – Developmental therapeutics
Resources:
Abstract
4748 - Phase 1/2 study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumors
Presenter: Ryan Corcoran
Session: Poster Discussion – Developmental therapeutics
Resources:
Abstract
4556 - Genomic Profiling of Three Pathways through Molecular Profiling-based Assignment of Cancer Therapy (NCI- MPACT)
Presenter: Alice Chen
Session: Poster Discussion – Developmental therapeutics
Resources:
Abstract
4548 - Precision Medicine: Preliminary Results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT 2) Study.
Presenter: Apostolia Maria Tsimberidou
Session: Poster Discussion – Developmental therapeutics
Resources:
Abstract
1915 - A Phase I study of ATR inhibitor, AZD6738, as monotherapy in advanced solid tumours (PATRIOT Part A, B)
Presenter: Magnus Dillon
Session: Poster Discussion – Developmental therapeutics
Resources:
Abstract
4517 - Updated results of the PARP1/2 inhibitor pamiparib in combination with low-dose (ld) temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumors
Presenter: Agostina Stradella
Session: Poster Discussion – Developmental therapeutics
Resources:
Abstract
2588 - Safety, antitumor activity, and pharmacokinetics (PK) of pamiparib (BGB-290), a PARP1/2 inhibitor, in patients (pts) with advanced solid tumors: updated phase 1 dose-escalation/expansion results
Presenter: Mark Voskoboynik
Session: Poster Discussion – Developmental therapeutics
Resources:
Abstract
3575 - Safety, Anti-Tumor Activity, and Biomarker Results of the HER2-Targeted Bispecific Antibody ZW25 in HER2-Expressing Solid Tumors
Presenter: Funda Meric-Bernstam
Session: Poster Discussion – Developmental therapeutics
Resources:
Abstract
1831 - First in human, a phase I study of ISU104, a novel ErbB3 monoclonal antibody, in patients with advanced solid tumors
Presenter: Sung-Bae Kim
Session: Poster Discussion – Developmental therapeutics
Resources:
Abstract
6587 - Immune activation with a novel immune switch anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) in phase I/II first-in-human MATINS trial in patients with advanced solid tumors
Presenter: Petri Bono
Session: Poster Discussion – Developmental therapeutics
Resources:
Abstract